Investors
AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap
-
Good growth in both Business Areas and continued profitability improvement
comments by the ceoThe companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy.
![Fredrik Dalborg Q2 2024 VD Addlife]()
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.
AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.
AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.
Target fulfilment 2023
Earnings growth
Profitability
Dividend
Contact us!
The investor pages contain all published financial information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.
Contact: ir@add.life
IR- and press contacts
Subscribe
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.